Reproducibility of PD-L1 scoring for immune cells in NSCLC. A study from the French group of thoracic pathologists PATTERN

Sylvie Lantuejoul , Lucie Tixier , Nolwenn Le Stang , Isabelle Rouquette
LABORATORY INVESTIGATION 98 738 -738

2018
Programmed Death Ligand1 (PD-L1) expression in a cohort of 39 pleomorphic pleural malignant mesotheliomas (MMs), compared to conventional mesotheliomas

Francoise Galateau Salle , Nolwenn Le Stang , Francesca Damiola , Jean-Claude Pairon
MODERN PATHOLOGY 31 733 -733

2018
2017
Café doc sur la nouvelle interface HAL (28 septembre 2017)(22/09/17)

Olga M Sinilnikova , Marie-Gabrielle Dondon , Séverine Eon-Marchais , Francesca Damiola

OA09.03 MESOMICS Project: Molecular Characterization of Malignant Pleural Mesothelioma Using a Multi-Omic Approach

F. Damiola , S. Lantuejoul , S. Boyault , L. Fernandez-Cuesta
Journal of Thoracic Oncology 16 ( 3)

2021
71 Rare, evolutionary unlikely missense substitutions in CHEK2 confer increased risk of breast cancer

F. Le Calvez , F. Lesueur , F. Damiola , C. Voegele
Ejc Supplements 8 ( 5) 19

2010
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.

J. Adam , N. Le Stang , I. Rouquette , A. Cazes
Annals of Oncology 29 ( 4) 953 -958

182
2018
OA08.02 A Multidisciplinary Multi-Omics Study of Spatial and Temporal Tumor Evolution in Thoracic Cancers with Clinical Implications

N. Alcala , L. Mangiante , A. Poret , A. Gabriel
Journal of Thoracic Oncology 14 ( 10)

2019
MA12.01 Redefining Malignant Pleural Mesothelioma Types as a Continuum Uncovers Immune-Vascular Interactions

N. Alcala , L. Mangiante , N. Le Stang , C. Gustafson
Journal of Thoracic Oncology 14 ( 10)

1
2019
40
2018
17
2011